COEPWHIGH SIGNALFINANCIAL10-K

COEPW underwent a dramatic financial transformation with debt increasing 650% and operating losses deepening 29.7% while simultaneously raising significant capital that boosted stockholders' equity by 325.8%.

The massive debt increase combined with worsening operating losses suggests either aggressive expansion funding or potential financial distress, requiring immediate investor attention. However, the substantial equity raise and liability reduction indicate possible strategic recapitalization or significant new investment in the business.

Comparing 2026-03-19 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

COEPW's financial profile changed dramatically with total debt spiking 650% to $1.1M and operating losses deepening to -$13.0M, while simultaneously raising substantial capital that increased stockholders' equity by 325.8% to $13.6M and current assets by 599.2% to $7.4M. The company significantly reduced total liabilities by 58.6% and current liabilities by 60.8%, though cash declined 55.4% to $404K despite the apparent capital raise. This mixed picture suggests either a major recapitalization event or acquisition activity, but the declining cash position and deepening losses amid reduced R&D spending creates uncertainty about the company's strategic direction and financial sustainability.

FINANCIAL STATEMENT CHANGES
Total Debt
Balance Sheet
+650%
$150K$1.1M

Debt increased 650% — substantial leverage increase; assess whether deployed for growth or covering losses.

Current Assets
Balance Sheet
+599.2%
$1.1M$7.4M

Current assets grew 599.2% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+325.8%
$3.2M$13.6M

Equity base grew 325.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+81.3%
$8.9M$16.2M

Asset base grew 81.3% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
-60.8%
$4.5M$1.8M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-58.6%
$5.0M$2.1M

Liabilities reduced 58.6% — deleveraging improves balance sheet strength and financial flexibility.

Cash & Equivalents
Balance Sheet
-55.4%
$907K$404K

Cash declined 55.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Interest Expense
P&L
-50.7%
$218K$108K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

R&D Expense
P&L
-45.2%
$2.3M$1.3M

R&D spending cut 45.2% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
-29.7%
-$10.1M-$13.0M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-28
ADDED
Management s Discussion and Analysis of Financial Condition and Results of Operations 32 7A.
This report includes our audited consolidated financial statements as of and for the years ended December 31, 2025 and December 31, 2024.
The biopharmaceutical division focuses on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases.
Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The technology division focuses on enhancing operational capabilities through advanced technologies.
+7 more — sign up free →
REMOVED
Management s Discussion and Analysis of Financial Condition and Results of Operations 33 7A.
This report includes our audited consolidated financial statements as of and for the year ended December 31, 2024.
This report also includes our audited consolidated financial statements as of and for the year ended December 31, 2023.
Our current business model is designed around furthering the development of our current product portfolio.
Our biopharmaceutical division is continually exploring partnership opportunities with companies that have novel therapies in various stages of development or companies with technologies that improve the way that drugs are delivered to patients.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →